Glycosylation state of vWF in circulating extracellular vesicles serves as a novel biomarker for predicting depression

Norihiro Yamada,Kana Tominaga,Naoomi Tominaga,Ayumi Kobayashi,Chihiro Niino,Yuta Miyagi,Hirotaka Yamagata,Shin Nakagawa
DOI: https://doi.org/10.1101/2024.03.24.24304794
2024-03-26
Abstract:The clinical diagnosis of major depressive disorder (MDD), a heterogeneous disorder, still depends on subjective information in terms of various symptoms regarding mood. Detecting extracellular vesicles (EVs) in blood may result in finding a diagnostic biomarker that reflects the depressive stage of patients with MDD. Here, we report the results on the glycosylation pattern of enriched plasma EVs from patients with MDD and age-matched healthy subjects. In this cohort, the levels of (wheat germ) agglutinin (WGA), -acetyl glucosamine (GlcNAc) and -acetylneuraminic acid (Neu5Ac, sialic acid) - binding lectin, were significantly decreased in patients with MDD in depressive state compared to healthy subjects (area under the curve (AUC): 0.87 (95% confidence interval (CI) 0.76 - 0.97)) and in remission state (AUC: 0.88 (95% CI 0.72 - 1.00)). Furthermore, proteome analysis revealed that the von Willebrand factor (vWF) was a significant factor recognized by WGA. WGA-binding vWF antigen differentiated patients with MDD versus healthy subjects (AUC: 0.92 (95% CI 0.82 - 1.00)) and the same patients with MDD in depressive versus remission state (AUC: 0.98 (95% CI 0.93 - 1.00)). In this study, the change patterns in the glycoproteins contained in plasma EVs support the usability of testing to identify patients who are at increased risk of depression during antidepressant treatment.
Psychiatry and Clinical Psychology
What problem does this paper attempt to address?